Testicular Yolk Sac Tumor
Symptoms, Doctors, Treatments, Advances & More

Testicular Yolk Sac Tumor Overview

Save information for later
Sign Up

Learn About Testicular Yolk Sac Tumor

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Testicular Yolk Sac Tumor Local Doctors?
Advanced in Testicular Yolk Sac Tumor
Advanced in Testicular Yolk Sac Tumor

St. Vincent Regional Hospital - Cancer Centers Of Montana

1315 Golden Valley Circle, 
Billings, MT 
Experience:
14+ years
Languages Spoken:
English, Spanish
Accepting New Patients
Offers Telehealth

Dr. Connor completed an undergraduate degree in Biochemistry at the University of Virginia and later earned her Medical Doctorate at the University of Virginia School of Medicine. She then completed her Obstetrics & Gynecology Residency training at Brown University and Gynecologic Oncology fellowship training at the Cleveland Clinic. She is board-certified in both obstetrics and gynecology and gynecologic oncology. Her clinical interests include preventing, diagnosing, and treating ovarian, uterine, cervical, vaginal and vulvar cancers. Dr. Connor moved to Montana to ensure comprehensive access to gynecologic oncology services in the region.“I care deeply for my patients and work hard for them to have the highest level of care and autonomy in their care.”When not seeing patients, Dr. Connor spends her time with her husband, two children, and two family dogs. They spend most of their time outside, whether skiing, hiking, or catching a soccer game. Dr. Connor is rated as an Advanced provider by MediFind in the treatment of Testicular Yolk Sac Tumor. She is also highly rated in 14 other conditions, according to our data. Her clinical expertise encompasses Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Endometrial Cancer, Bladder Reconstruction, and Hysterectomy. Dr. Connor is board certified in American Board Of Obstetrics And Gynecology and American Board Of Obstetrics And Gynecology. Dr. Connor is currently accepting new patients.

Advanced in Testicular Yolk Sac Tumor
Advanced in Testicular Yolk Sac Tumor

Aurora Gynecologic Oncology

8905 W Lincoln Ave, Ste 407, 
West Allis, WI 
Languages Spoken:
English

Scott Kamelle is an Oncologist practicing medicine in West Allis, Wisconsin. Dr. Kamelle is rated as an Advanced provider by MediFind in the treatment of Testicular Yolk Sac Tumor. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Ureteroscopy, and Bladder Reconstruction. Dr. Kamelle is board certified in American Board Of Obstetrics & Gynecology, Gynecologic Oncology.

 
 
 
 
Learn about our expert tiers
Learn More
Advanced in Testicular Yolk Sac Tumor
Hematology | Oncology
Advanced in Testicular Yolk Sac Tumor
Hematology | Oncology

Vince Lombardi Cancer Clinic

W180N11070 River Ln, 
Germantown, WI 
Languages Spoken:
English
Offers Telehealth

Timothy Goggins is a Hematologist and an Oncologist practicing medicine in Germantown, Wisconsin. Dr. Goggins is rated as an Advanced provider by MediFind in the treatment of Testicular Yolk Sac Tumor. He is also highly rated in 38 other conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Colorectal Cancer, Familial Colorectal Cancer, and Testicular Yolk Sac Tumor. Dr. Goggins is board certified in American Board Of Internal Medicine, Hematology.

What are the latest Testicular Yolk Sac Tumor Clinical Trials?
Phase II Basket Study to Evaluate the Tissue-agnostic Efficacy of Anti-Programmed Cell Death Protein 1 (Anti-PD1) Monoclonal Antibody in Patients With Advanced Rare Tumors

Summary: The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors. The study aims to treat rare malignancies with PD-L1 expression (CPS ≥ 10), regardless of the tumor's tissue type or location. Patients who have not responded to standard treatments will be included, and ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Selected Advanced or Metastatic Solid Tumors

Summary: This is a first-in-human (FIH) clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of BGB-B2033 administered as monotherapy and in combination with tislelizumab, with or without bevacizumab. The study will enroll participants with locally advanced or metastatic hepatocellular carcinoma (HCC), alpha-fetoprotein (AFP)-pr...